year alliance with the World Health Organization (WHO) to provide Coartem, Novartis’ breakthrough malaria medicine, without profit for use by public health systems in developing countries. Novartis provided Coartem for $1.57 per treatment and WHO distributed it through governments of malaria-endemic countries. Coartem obtained regulatory approval from three countries in 1999 and from the FDA in 2009. By 2013 Novartis had provided 500 million treatments without profit, making it one of the largest access-to-medicine programs.
Globalizing Novartis Research
We Write Essays for Students
Tell us about your assignment and we will find the best writer for your paper
Get Help Now!Vasella’s boldest move came in 2002, when he abandoned the traditional drug-development model, declaring Novartis would only investigate diseases for which new drugs were desperately needed and where there were a solid scientific basis or hypothesis of the mechanisms (genetic and/or pathways) leading to the target illnesses. While other CEOs saw the pursuit of rare diseases as commercial suicide, Vasella believed many of the illnesses shared genetic underpinnings with more common ailments.14
Historically, both Sandoz and Ciba leaders felt they could attract the best scientists in the world to work in Basel. In contrast, Vasella felt the company needed to be where the talent pool was located and that Novartis needed to attract the top scientists in the U.S. Consequently, he shifted Novartis’s global research headquarters to the U.S. by establishing the Novartis Institutes for Biomedical Research (NIBR) in Cambridge, MA near Harvard University and MIT. While the Basel research site was maintained, the company closed its research center in New Jersey, transferring key scientists to Cambridge. The original investment was $1 billion.
To head NIBR, Vasella recruited Mark Fishman, M.D., chief of cardiology at Massachusetts General Hospital, a geneticist and top scientist. “We needed an M.D. with a modern approach to research with vast knowledge of molecular biology and genetics, and with broad clinical experience,” Vasella explained. His decisions set off a firestorm in Basel. Concerns were voiced about “abandoning Basel” and hiring an American academic medical scientist without industry experience.
Fishman recalled, “The original idea was actually to have a research site in the Boston-Cambridge area, but I thought it had to be the headquarters for research. You can’t change an organization by modifying it from within. Second, research could not be part of pharma. It had to be discovery- driven, not financially-driven by marketing as most pharmaceutical companies were.”
Vasella agreed on both points, having Fishman report directly to him rather than Ebeling. This also led to internal criticism because the pharmaceutical group felt strongly it had to control its own research. “Separating research out,” Vasella said, “allowed me to protect the investment; otherwise, people start to cut it due to budgetary pressures.”
NIBR’s mission was to discover innovative new drugs that would change the practice of medicine. Traditionally, drug researchers discovered medicines by bombarding an illness with a variety of chemicals until they hit a combination that treated it. A research strategy based on molecular pathways, by contrast, zeroed in on the exact molecular mechanisms that caused a disease.15 Fishman cancelled 30% of research projects to shift the focus to rare diseases. “First, we have to understand the unmet need,” he explained, “and then the mechanism and the path of physiology in order to make a medicine.”
[sg_popup id=2]
PLACE THIS ORDER OR A SIMILAR ORDER WITH NURSING HOMEWORK HELP TODAY AND GET AN AMAZING DISCOUNT
The post year alliance with the World Health Organization (WHO) to provide Coartem, Novartis’ breakthrough malaria medicine, without profit for use by public health systems in developing countries. Novartis provided Coartem for $1.57 per treatment and WHO distributed it through governments of malaria-endemic countries. Coartem obtained regulatory approval from three countries in 1999 and from the FDA in 2009. By 2013 Novartis had provided 500 million treatments without profit, making it one of the largest access-to-medicine programs. appeared first on My Nursing Papers.
Welcome to originalessaywriters.com, our friendly and experienced essay writers are available 24/7 to complete all your assignments. We offer high-quality academic essays written from scratch to guarantee top grades to all students. All our papers are 100% plagiarism-free and come with a plagiarism report, upon request
Tell Us “Write My Essay for Me” and Relax! You will get an original essay well before your submission deadline.
